These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

913 related items for PubMed ID: 25046268

  • 1. PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.
    Marais AD, Kim JB, Wasserman SM, Lambert G.
    Pharmacol Ther; 2015 Jan; 145():58-66. PubMed ID: 25046268
    [Abstract] [Full Text] [Related]

  • 2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D, Pöss J, Böhm M, Laufs U.
    J Am Coll Cardiol; 2013 Oct 15; 62(16):1401-8. PubMed ID: 23973703
    [Abstract] [Full Text] [Related]

  • 3. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A, Watts GF.
    Clin Ther; 2013 Aug 15; 35(8):1082-98. PubMed ID: 23932550
    [Abstract] [Full Text] [Related]

  • 4. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.
    Circulation; 2015 Oct 27; 132(17):1648-66. PubMed ID: 26503748
    [Abstract] [Full Text] [Related]

  • 5. PCSK9: a key modulator of cardiovascular health.
    Seidah NG, Awan Z, Chrétien M, Mbikay M.
    Circ Res; 2014 Mar 14; 114(6):1022-36. PubMed ID: 24625727
    [Abstract] [Full Text] [Related]

  • 6. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo.
    Schiele F, Park J, Redemann N, Luippold G, Nar H.
    J Mol Biol; 2014 Feb 20; 426(4):843-52. PubMed ID: 24252255
    [Abstract] [Full Text] [Related]

  • 7. Anti-PCSK9 therapies for the treatment of hypercholesterolemia.
    Hooper AJ, Burnett JR.
    Expert Opin Biol Ther; 2013 Mar 20; 13(3):429-35. PubMed ID: 23240807
    [Abstract] [Full Text] [Related]

  • 8. PCSK9 inhibition: current concepts and lessons from human genetics.
    Rodriguez F, Knowles JW.
    Curr Atheroscler Rep; 2015 Mar 20; 17(3):487. PubMed ID: 25637042
    [Abstract] [Full Text] [Related]

  • 9. Understanding PCSK9 and anti-PCSK9 therapies.
    McKenney JM.
    J Clin Lipidol; 2015 Mar 20; 9(2):170-86. PubMed ID: 25911073
    [Abstract] [Full Text] [Related]

  • 10. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH, O'Reilly P, Lu C, Gomes J, Lagace TA, Basak A.
    Eur J Med Chem; 2015 Mar 06; 92():890-907. PubMed ID: 25679794
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of proprotein convertase subtilisin/kexin type 9: focus on potential clinical and therapeutic implications for low-density lipoprotein cholesterol lowering.
    Lose JM, Dorsch MP, Bleske BE.
    Pharmacotherapy; 2013 Apr 06; 33(4):447-60. PubMed ID: 23553812
    [Abstract] [Full Text] [Related]

  • 12. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects.
    Tavori H, Rashid S, Fazio S.
    Atherosclerosis; 2015 Feb 06; 238(2):264-70. PubMed ID: 25544176
    [Abstract] [Full Text] [Related]

  • 13. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z, Baass A, Genest J.
    Clin Chem; 2014 Nov 06; 60(11):1380-9. PubMed ID: 25248569
    [Abstract] [Full Text] [Related]

  • 14. An update on the clinical development of proprotein convertase subtilisin kexin 9 inhibitors, novel therapeutic agents for lowering low-density lipoprotein cholesterol.
    Ling H, Burns TL, Hilleman DE.
    Cardiovasc Ther; 2014 Apr 06; 32(2):82-8. PubMed ID: 24354905
    [Abstract] [Full Text] [Related]

  • 15. [Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors].
    Avci A, Demir K, Altunkeser BB.
    Turk Kardiyol Dern Ars; 2014 Oct 06; 42 Suppl 2():56-67. PubMed ID: 25693363
    [Abstract] [Full Text] [Related]

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL.
    Nutr Metab Cardiovasc Dis; 2011 Nov 06; 21(11):835-43. PubMed ID: 21943799
    [Abstract] [Full Text] [Related]

  • 17. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ, Li JJ.
    Clin Chim Acta; 2014 Apr 20; 431():148-53. PubMed ID: 24518357
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of PCSK9: a novel approach for the treatment of dyslipidemia.
    Stawowy P, Just IA, Kaschina E.
    Coron Artery Dis; 2014 Jun 20; 25(4):353-9. PubMed ID: 24667128
    [Abstract] [Full Text] [Related]

  • 19. New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
    Giunzioni I, Tavori H.
    Vasc Health Risk Manag; 2015 Jun 20; 11():493-501. PubMed ID: 26345307
    [Abstract] [Full Text] [Related]

  • 20. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia.
    Switzer MP, Nwosu AC, Juan ZS, Mukherjee D.
    Cardiovasc Hematol Agents Med Chem; 2013 Dec 20; 11(4):281-8. PubMed ID: 24164109
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.